FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308973881> ?p ?o ?g. }

• W4308973881 abstract "Atypical hemolytic-uremic syndrome (aHUS) is a severe thrombotic microangiopathy in which kidney involvement is common. aHUS can be due to either genetic or acquired abnormalities, with most abnormalities affecting the alternative complement pathway. Several genetic factors/alterations can drive the clinical presentation, therapeutic response, and risk of recurrence, especially recurrence following kidney transplantation. We report here the case of a 22-year-old man who developed a severe form of aHUS. Renal biopsy revealed thrombotic microangiopathy and features of chronic renal damage. Despite two eculizumab infusions, the patient remained dialysis dependent. Two novel rare variants, c.109G>A (p.E37K) and c.159 C>A (p.Y53*), were identified in the factor H-related 2 (FHR2) gene, and western blot analysis revealed a significant reduction in the level of FHR2 protein in the patient's serum. Although FHR2 involvement in complement 3 glomerulopathy has been reported previously, a role for FRH2 as a complement modulator has not yet been definitively shown. In addition, no cases of aHUS in individuals with FHR2 variants have been reported. Given the role of FHRs in the complement system and the fact that this patient was a candidate for a kidney transplant, we studied the relevance of low FHR2 plasma levels through a set of functional in vitro assays. The aim of our work was to determine if low FHR2 plasma levels could influence complement control at the endothelial surface with a view to identifying a therapeutic approach tailored to this specific patient. Interestingly, we observed that low FHR2 levels in the patient's serum could induce complement activation, as well as C5b-9 deposition on human endothelial cells, and affected cell morphology. As C5b-9 deposition is a prerequisite for endothelial cell damage, these results suggest that extremely low FHR2 plasma levels increase the risk of aHUS. Given their ability to reduce C5b-9 deposition, recombinant FHR2 and eculizumab were tested in vitro and found to inhibit hemolysis and endothelial cell surface damage. Both molecules showed effective and comparable profiles. Based on these results, the patient underwent a kidney transplant, and received eculizumab as induction and maintenance therapy. Five years after transplantation, the patient remains in good general health, with stable graft function and no evidence of disease recurrence. To our knowledge, this is first reported case of an aHUS patient carrying FHR2 mutations and provides an example of a translational therapeutic approach in kidney transplantation." @default.
• W4308973881 created "2022-11-20" @default.
• W4308973881 creator A5001391327 @default.
• W4308973881 creator A5015868168 @default.
• W4308973881 creator A5036694006 @default.
• W4308973881 creator A5037939517 @default.
• W4308973881 creator A5048512133 @default.
• W4308973881 creator A5050180958 @default.
• W4308973881 creator A5055505398 @default.
• W4308973881 creator A5058402515 @default.
• W4308973881 creator A5067381987 @default.
• W4308973881 creator A5074615051 @default.
• W4308973881 creator A5079021408 @default.
• W4308973881 date "2022-11-14" @default.
• W4308973881 modified "2023-09-26" @default.
• W4308973881 title "Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation" @default.
• W4308973881 cites W1576495961 @default.
• W4308973881 cites W1722566242 @default.
• W4308973881 cites W1966820620 @default.
• W4308973881 cites W1968817172 @default.
• W4308973881 cites W1976386747 @default.
• W4308973881 cites W1997599954 @default.
• W4308973881 cites W2009255343 @default.
• W4308973881 cites W2021988356 @default.
• W4308973881 cites W2082883706 @default.
• W4308973881 cites W2089966039 @default.
• W4308973881 cites W2103573567 @default.
• W4308973881 cites W2123753762 @default.
• W4308973881 cites W2130599966 @default.
• W4308973881 cites W2139585104 @default.
• W4308973881 cites W2139588645 @default.
• W4308973881 cites W2143431905 @default.
• W4308973881 cites W2503282635 @default.
• W4308973881 cites W2565152113 @default.
• W4308973881 cites W2746096526 @default.
• W4308973881 cites W2902241490 @default.
• W4308973881 cites W2955977081 @default.
• W4308973881 cites W2974260575 @default.
• W4308973881 cites W3001004552 @default.
• W4308973881 cites W3041433417 @default.
• W4308973881 doi "https://doi.org/10.3389/fimmu.2022.1008294" @default.
• W4308973881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36451836" @default.
• W4308973881 hasPublicationYear "2022" @default.
• W4308973881 type Work @default.
• W4308973881 citedByCount "1" @default.
• W4308973881 countsByYear W43089738812023 @default.
• W4308973881 crossrefType "journal-article" @default.
• W4308973881 hasAuthorship W4308973881A5001391327 @default.
• W4308973881 hasAuthorship W4308973881A5015868168 @default.
• W4308973881 hasAuthorship W4308973881A5036694006 @default.
• W4308973881 hasAuthorship W4308973881A5037939517 @default.
• W4308973881 hasAuthorship W4308973881A5048512133 @default.
• W4308973881 hasAuthorship W4308973881A5050180958 @default.
• W4308973881 hasAuthorship W4308973881A5055505398 @default.
• W4308973881 hasAuthorship W4308973881A5058402515 @default.
• W4308973881 hasAuthorship W4308973881A5067381987 @default.
• W4308973881 hasAuthorship W4308973881A5074615051 @default.
• W4308973881 hasAuthorship W4308973881A5079021408 @default.
• W4308973881 hasBestOaLocation W43089738811 @default.
• W4308973881 hasConcept C111684460 @default.
• W4308973881 hasConcept C126322002 @default.
• W4308973881 hasConcept C14356644 @default.
• W4308973881 hasConcept C159654299 @default.
• W4308973881 hasConcept C179369057 @default.
• W4308973881 hasConcept C189446657 @default.
• W4308973881 hasConcept C203014093 @default.
• W4308973881 hasConcept C2777637130 @default.
• W4308973881 hasConcept C2777878052 @default.
• W4308973881 hasConcept C2777991916 @default.
• W4308973881 hasConcept C2779134260 @default.
• W4308973881 hasConcept C2779978075 @default.
• W4308973881 hasConcept C2780091579 @default.
• W4308973881 hasConcept C2780199430 @default.
• W4308973881 hasConcept C2780303639 @default.
• W4308973881 hasConcept C2780368995 @default.
• W4308973881 hasConcept C2911091166 @default.
• W4308973881 hasConcept C71924100 @default.
• W4308973881 hasConcept C90924648 @default.
• W4308973881 hasConceptScore W4308973881C111684460 @default.
• W4308973881 hasConceptScore W4308973881C126322002 @default.
• W4308973881 hasConceptScore W4308973881C14356644 @default.
• W4308973881 hasConceptScore W4308973881C159654299 @default.
• W4308973881 hasConceptScore W4308973881C179369057 @default.
• W4308973881 hasConceptScore W4308973881C189446657 @default.
• W4308973881 hasConceptScore W4308973881C203014093 @default.
• W4308973881 hasConceptScore W4308973881C2777637130 @default.
• W4308973881 hasConceptScore W4308973881C2777878052 @default.
• W4308973881 hasConceptScore W4308973881C2777991916 @default.
• W4308973881 hasConceptScore W4308973881C2779134260 @default.
• W4308973881 hasConceptScore W4308973881C2779978075 @default.
• W4308973881 hasConceptScore W4308973881C2780091579 @default.
• W4308973881 hasConceptScore W4308973881C2780199430 @default.
• W4308973881 hasConceptScore W4308973881C2780303639 @default.
• W4308973881 hasConceptScore W4308973881C2780368995 @default.
• W4308973881 hasConceptScore W4308973881C2911091166 @default.
• W4308973881 hasConceptScore W4308973881C71924100 @default.
• W4308973881 hasConceptScore W4308973881C90924648 @default.
• W4308973881 hasLocation W43089738811 @default.
• W4308973881 hasLocation W43089738812 @default.
• W4308973881 hasLocation W43089738813 @default.

• next